33.39

0.89% -0.30

Pre-market: 34.22 0.83 +2.49%

Tg Therapeutics Inc (TGTX)

Overview News Price History Option Chain Financials Why TGTX Down? Discussions Forecast Stock Split

Tg Therapeutics Inc stock is traded at $33.39, with a volume of 1.43M. It is down -0.89% in the last 24 hours and up +14.08% over the past month. TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.

Previous Close:

$33.69

Open:

$33.51

24h Volume:

1.43M

Relative Volume:

0.69

Market Cap:

$5.33B

Revenue:

$616.29M

Net Income/Loss:

$447.18M

P/E Ratio:

12.02

EPS:

2.7771

Net Cash Flow:

$-24.99M

1W Performance:

+0.51%

1M Performance:

+14.08%

6M Performance:

-8.52%

1Y Performance:

-10.36%

1-Day Range:

$33.05

$33.89

1-Week Range:

$33.05

$35.33

52-Week Range:

$25.28

$46.48

Tg Therapeutics Inc Stock (TGTX) Company Profile

Name

Tg Therapeutics Inc

Sector

Healthcare (1110)

Industry

Biotechnology (624)

Phone

(212) 554-4484

Address

2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY

Employee

399

Twitter

@TGTherapeutics

Next Earnings Date

2025-03-03

Latest SEC Filings

TGTX's Discussions on Twitter

Compare TGTX vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TGTX Tg Therapeutics Inc	33.39	5.33B	616.29M	447.18M	-24.99M	2.7771
VRTX Vertex Pharmaceuticals Inc	431.86	109.85B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	760.27	80.38B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	765.43	47.60B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	319.52	42.63B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.03	35.19B	606.42M	-1.28B	-997.58M	-6.403

Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-06-25	Resumed	H.C. Wainwright	Buy
Jul-10-25	Resumed	Goldman	Neutral
Oct-29-24	Initiated	TD Cowen	Buy
Aug-02-23	Upgrade	Goldman	Sell → Neutral
Jun-26-23	Resumed	Jefferies	Buy
May-20-22	Initiated	BofA Securities	Underperform
Feb-23-22	Reiterated	B. Riley Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-20-21	Initiated	Goldman	Neutral
Apr-19-21	Reiterated	H.C. Wainwright	Buy
Sep-01-20	Initiated	JP Morgan	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Jun-05-20	Initiated	Evercore ISI	Outperform
Jan-17-20	Reiterated	H.C. Wainwright	Buy
Nov-27-19	Resumed	B. Riley FBR	Buy
Feb-06-19	Resumed	Jefferies	Buy
Sep-25-18	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-18	Reiterated	B. Riley FBR, Inc.	Buy
Dec-01-17	Resumed	B. Riley FBR, Inc.	Buy
Nov-14-17	Resumed	H.C. Wainwright	Buy
Apr-25-17	Initiated	Jefferies	Buy
Mar-06-17	Reiterated	FBR & Co.	Outperform
Oct-06-16	Resumed	Brean Capital	Buy
May-27-16	Initiated	SunTrust	Buy
Dec-01-15	Initiated	FBR Capital	Outperform
Sep-09-15	Initiated	Raymond James	Strong Buy
Aug-12-15	Resumed	H.C. Wainwright	Buy
Jun-19-15	Reiterated	Brean Capital	Buy
Dec-11-14	Reiterated	ROTH Capital	Buy
Dec-10-14	Reiterated	ROTH Capital	Buy

View All

Tg Therapeutics Inc Stock (TGTX) Latest News

Apr 07, 2026

Fed Meeting: Can TG Therapeutics Inc expand into new marketsMarket Trend Report & Daily Momentum Trading Reports - baoquankhu1.vn

Apr 07, 2026

Gains Recap: Is TG Therapeutics Inc undervalued by DCF analysis - baoquankhu1.vn

Apr 07, 2026

Apr 05, 2026

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Apr 05, 2026

Apr 04, 2026

TGTX PE Ratio & Valuation, Is TGTX Overvalued - intellectia.ai

Apr 04, 2026

TG Therapeutics Inc (NASDAQ:TGTX): An Affordable Growth Stock with Strong Momentum - ChartMill

Apr 04, 2026